Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

por Sathe, A, Guerth, F, Cronauer, M V, Heck, M M, Thalgott, M, Gschwend, J E, Retz, M, Nawroth, R
Publicado 2014